1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

FTC Finalizes ‘All-Natural’ Personal-Care Settlements, Offers A Word On ‘Natural’

 
• By Ryan Nelson

The Federal Trade Commission announces unanimous approval of final consent orders requiring four personal-care companies to make only properly substantiated “all-natural” and “100% natural” product claims from this point forward. In response to a submitted comment, FTC offers perspective on plain “natural” claims based on its understanding of how consumers interpret the term.

Four personal-care product marketers have agreed to have competent and reliable evidence to support any “all-natural” or “100% natural” claims they make going forward under final settlement terms announced by the Federal Trade Commission July 13.

Approved by a unanimous commission vote, the final consent orders also bar the companies from misrepresenting “the extent to which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

UK ‘Snapshot’ Sampling: Most Third-Party Beauty On Four Ecommerce Sites ‘Likely’ Counterfeit

 
• By Eileen Francis

UK consumer advocacy organization finds more than two-thirds of 34 skin care and makeup products it purchased from third party sellers on major ecommerce sites are fake.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By Lauren Nardella

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.

More from Policy & Regulation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 
• By Malcolm Spicer

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.